Daily Digest
Pathos AI, Bristol Myers, Tempus AI partner for drug development
Published Friday, October 23, 2026 · Updated October 23
Narrative Spectrum
- Single-Source Coverage — 1 source
What We Know — Key Points
Key points are extracted by an AI model and may contain errors or omissions. Always check the original sources.- Pathos AI raised $237 million in a Series E funding round led by Bristol Myers, valuing the company at about $3 billion.
What Is Claimed — Perspectives
Single-Source Coverage
- Channel News Asia
Pathos AI has announced a collaboration with Bristol Myers Squibb and Tempus AI to develop AI tools for drug development in Alzheimer's disease and other neurological disorders. Pathos AI also raised $237 million in a Series E funding round led by Bristol Myers, valuing the company at approximately $3 billion.
- Read original →· Oct 23
AI-Generated Content
- This topic was generated by an AI system.
- Key points, perspectives, bias labels, and categorisation may contain errors.
- This is not journalism. Do not rely on this content for critical decisions.
- Read our full AI disclaimer for details.